Y-mAbs Therapeutics, Inc. (YMAB) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1243605,
    "name": "Y-mAbs Therapeutics, Inc.",
    "stock_name": "Y-mAbs Therapeutics, Inc.",
    "full_name": "Y-mAbs Therapeutics, Inc.",
    "name_url": "stocks-analysis/y-mabs-therapeutics-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "8.61",
    "chg": 0.02,
    "chgp": "0.23%",
    "dir": 1,
    "prev_price": "8.59",
    "mcapval": "390.32",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2305,
    "indexname": "S&P 500",
    "isin": "US9842411095",
    "curr_date": "Sep 17",
    "curr_time": "",
    "bse_nse_vol": "0 ",
    "exc_status": "Active",
    "traded_date": "Sep 17, 2025",
    "traded_date_str": "2025 09 17",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/y-mabs-therapeutics-inc-1243605-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is Y-mAbs Therapeutics, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-y-mabs-therapeutics-inc-technically-bullish-or-bearish-3547731",
        "imagepath": "",
        "date": "2025-09-20 20:01:52",
        "description": "As of 11 September 2025, the technical trend for Y-mAbs Therapeutics, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, and the daily moving averages also indicate a bullish stance. However, the monthly MACD is only mildly bullish, and the Bollinger Bands show a mildly bearish signal on the monthly timeframe. The KST is bullish on the weekly but bearish on the monthly, while the OBV is bullish across both timeframes. \n\nIn terms of performance, the stock has underperformed compared to the S&P 500 across multiple periods, with a 1-year return of -39.83% versus the S&P's 17.14%, and a 5-year return of -79.18% compared to the S&P's 96.61%. Overall, the current technical stance is bullish, albeit with some mixed signals in the longer-term indicators...."
      },
      {
        "title": "Is Y-mAbs Therapeutics, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-y-mabs-therapeutics-inc-overvalued-or-undervalued-3544016",
        "imagepath": "",
        "date": "2025-09-20 18:35:15",
        "description": "As of 25 February 2021, the valuation grade for Y-mAbs Therapeutics, Inc. has moved from does not qualify to risky, indicating a significant downgrade in its investment appeal. The company appears to be overvalued given its current financial metrics, including a Price to Book Value of 2.67 and an EV to Sales ratio of 2.02, which suggest that the stock is trading at a premium compared to its underlying assets and sales performance. Additionally, the company has a negative ROCE of -104.17% and a negative ROE of -31.56%, highlighting its struggles in generating returns for shareholders.\n\nIn comparison to its peers, Y-mAbs has a P/E ratio of -17.56, which is significantly worse than Lexicon Pharmaceuticals, Inc. at -3.53 and scPharmaceuticals, Inc. at -4.39, indicating that it is underperforming relative to its industry counterparts. Furthermore, the company's stock has underperformed against the S&P 500 over v..."
      }
    ],
    "total": 8,
    "sid": "1243605",
    "stock_news_url": "https://www.marketsmojo.com/news/y-mabs-therapeutics-inc-1243605"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Is Y-mAbs Therapeutics, Inc. technically bullish or bearish?

2025-09-20 20:01:52

As of 11 September 2025, the technical trend for Y-mAbs Therapeutics, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, and the daily moving averages also indicate a bullish stance. However, the monthly MACD is only mildly bullish, and the Bollinger Bands show a mildly bearish signal on the monthly timeframe. The KST is bullish on the weekly but bearish on the monthly, while the OBV is bullish across both timeframes. In terms of performance, the stock has underperformed compared to the S&P 500 across multiple periods, with a 1-year return of -39.83% versus the S&P's 17.14%, and a 5-year return of -79.18% compared to the S&P's 96.61%. Overall, the current technical stance is bullish, albeit with some mixed signals in the longer-term indicators....

Is Y-mAbs Therapeutics, Inc. overvalued or undervalued?

2025-09-20 18:35:15

As of 25 February 2021, the valuation grade for Y-mAbs Therapeutics, Inc. has moved from does not qualify to risky, indicating a significant downgrade in its investment appeal. The company appears to be overvalued given its current financial metrics, including a Price to Book Value of 2.67 and an EV to Sales ratio of 2.02, which suggest that the stock is trading at a premium compared to its underlying assets and sales performance. Additionally, the company has a negative ROCE of -104.17% and a negative ROE of -31.56%, highlighting its struggles in generating returns for shareholders. In comparison to its peers, Y-mAbs has a P/E ratio of -17.56, which is significantly worse than Lexicon Pharmaceuticals, Inc. at -3.53 and scPharmaceuticals, Inc. at -4.39, indicating that it is underperforming relative to its industry counterparts. Furthermore, the company's stock has underperformed against the S&P 500 over v...

View All News